Please use this identifier to cite or link to this item: https://doi.org/10.1128/JVI.02165-08
DC FieldValue
dc.titleMonoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection
dc.contributor.authorPrabhu, N.
dc.contributor.authorPrabakaran, M.
dc.contributor.authorHo, H.-T.
dc.contributor.authorVelumani, S.
dc.contributor.authorQiang, J.
dc.contributor.authorGoutama, M.
dc.contributor.authorKwang, J.
dc.date.accessioned2016-11-29T01:19:59Z
dc.date.available2016-11-29T01:19:59Z
dc.date.issued2009-03
dc.identifier.citationPrabhu, N., Prabakaran, M., Ho, H.-T., Velumani, S., Qiang, J., Goutama, M., Kwang, J. (2009-03). Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. Journal of Virology 83 (6) : 2553-2562. ScholarBank@NUS Repository. https://doi.org/10.1128/JVI.02165-08
dc.identifier.issn0022538X
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/131552
dc.description.abstractThe HA2 glycopolypeptide (gp) is highly conserved in all influenza A virus strains, and it is known to play a major role in the fusion of the virus with the endosomal membrane in host cells during the course of viral infection. Vaccines and therapeutics targeting this HA2 gp could induce efficient broad-spectrum immunity against influenza A virus infections. So far, there have been no studies on the possible therapeutic effects of monoclonal antibodies (MAbs), specifically against the fusion peptide of hemagglutinin (HA), upon lethal infections with highly pathogenic avian influenza (HPAI) H5N1 virus. We have identified MAb 1C9, which binds to GLFGAIAGF, a part of the fusion peptide of the HA2 gp. We evaluated the efficacy of MAb 1C9 as a therapy for influenza A virus infections. This MAb, which inhibited cell fusion in vitro when administered passively, protected 100% of mice from challenge with five 50% mouse lethal doses of HPAI H5N1 influenza A viruses from two different clades. Furthermore, it caused earlier clearance of the virus from the lung. The influenza virus load was assessed in lung samples from mice challenged after pretreatment with MAb 1C9 (24 h prior to challenge) and from mice receiving early treatment (24 h after challenge). The study shows that MAb 1C9, which is specific to the antigenically conserved fusion peptide of HA2, can contribute to the cross-clade protection of mice infected with H5N1 virus and mediate more effective recovery from infection. Copyright © 2009, American Society for Microbiology.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1128/JVI.02165-08
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMICROBIOLOGY
dc.description.doi10.1128/JVI.02165-08
dc.description.sourcetitleJournal of Virology
dc.description.volume83
dc.description.issue6
dc.description.page2553-2562
dc.description.codenJOVIA
dc.identifier.isiut000263650500015
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

103
checked on Jul 16, 2019

WEB OF SCIENCETM
Citations

98
checked on Jul 16, 2019

Page view(s)

12
checked on Jul 19, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.